不同剂量厄贝沙坦治疗慢性肾小球肾炎患者后尿蛋白的变化
DOI:
作者:
作者单位:

作者简介:

通讯作者:

基金项目:


Changes of Urine Protein in Patients with Chronic Glomerulonephritis After Different doses of Irbesartan Treatment
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
    摘要:

    目的观察慢性肾小球肾炎患者应用厄贝沙坦治疗后尿蛋白的变化,探讨高剂量厄贝沙坦治疗对尿蛋白的疗效。方法32例经肾活检确诊的慢性肾小球肾炎患者,所有患者24 h尿蛋白≥0.5 g/d,随机分为常规剂量组(口服厄贝沙坦0.15 g/d,n=16)和高剂量组(口服厄贝沙坦0.3 g/d,n=16),治疗8周后观察24 h尿蛋白和血钾、血肌酐及尿素氮水平。结果受试患者服用厄贝沙坦后尿蛋白均下降,常规剂量组尿蛋白较治疗前减少40%,而高剂量组尿蛋白较治疗前减少63%,两组血清钾、血肌酐及尿素氮水平均无明显改变。结论对慢性肾小球肾炎患者,高剂量厄贝沙坦在减少尿蛋白方面更为显效,且患者耐受性、医从性均较好。

    Abstract:

    Aim To investigate the changes of urine protein in patients with chronic glomerulonephritis after different doses of irbesartan treatment and find out whether there was a higher efficacy of high dose irbesartan. Methods 32 chronic glomerulonephritis patients were randomly and equally divided into normal dose group(oral irbesartan 0.15 g/d,n=16) and high dose group(oral irbesartan 0.3 g/d,n=16).Eight weeks later,24 h urine protein and serum potassium were measured. Results 24 h urine protein decreased by 40% in normal dose group and 63% in high dose group,while serum potassium had not changed in both groups. Conclusion High dose irbesartan in reducing urine protein in patients with chronic glomerulonephritis would be more marked,and the patient tolerance,from sexual health are good.

    参考文献
    相似文献
    引证文献
引用本文

陈伟.不同剂量厄贝沙坦治疗慢性肾小球肾炎患者后尿蛋白的变化[J].中国动脉硬化杂志,2010,18(11):909~910.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:2009-09-30
  • 最后修改日期:2010-10-13
  • 录用日期:
  • 在线发布日期: